A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
This is a Phase 2 open-label, single-treatment group, baseline-controlled study designed to
verify product safety, gather data on the percentage of subjects with pituitary tumors with
increased uptake of FolateScan in tumors and correlate the immunohistochemical staining
findings with the FolateScan images, in subjects with pituitary tumors.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Nelson Oyesiku, MD
Principal Investigator
Emory Hospital
United States: Food and Drug Administration
EC20.7
NCT01689727
September 2002
Name | Location |
---|---|
Emory Hospital | Atlanta, Georgia 30322 |